Intervention

albumin-bound paclitaxel

ClinicalTrials.gov intervention label

Clinical trials5

Recruiting0

Common conditions8

Lead sponsors shown5

Clinical trials

5 shown

Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC PatientsNCT06028633 · 2023-10-01

NOT_YET_RECRUITING

HR Positive, HER2 Negative Advanced Breast Cancer With Progression After Endocrine TherapyNCT05322720 · 2022-04-01

Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world StudyNCT05287308 · 2022-03-01

NOT_YET_RECRUITING

Neoadjuvant of Sintilimab Combined With Chemotherapy for Resectable NSCLC（neoSCORE）NCT04459611 · 2020-07-01

Albumin-Bound Paclitaxel and Gemcitabine in Patients With Untreated Stage IV or Recurrent Squamous Cell Lung CancersNCT02525653 · 2015-08-01

Common conditions

Advanced Non-squamous Non-small-cell Lung Cancer1 Breast Cancer1 Lung Cancer1 Metastatic Non-squamous Non Small Cell Lung Cancer1 Non-small Cell Lung Cancer1 Recurrent Non-Squamous Non-Small Cell Lung Cancer1 Solid Tumor, Adult1 Untreated Stage IV or Recurrent Squamous Cell Lung Cancers1

Leading sponsors

Chinese Academy of Medical Sciences1 Memorial Sloan Kettering Cancer Center1 Peking University First Hospital1 Second Affiliated Hospital, Zhejiang University, School of Medicine1 Taizhou EOC Pharma Co., Ltd.1

Trial status mix

NOT_YET_RECRUITING2

UNKNOWN2

COMPLETED1

Phase mix

PHASE24

NA1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.